Short Interest in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM) Decreases By 2.0%

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) was the target of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,189,611 shares, a decline of 2.0% from the October 15th total of 1,214,174 shares. Based on an average daily volume of 21,451 shares, the days-to-cover ratio is currently 55.5 days. Currently, 3.3% of the company’s shares are sold short.

In other news, Director James Lebar sold 200,000 shares of the business’s stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of $2.15, for a total transaction of $430,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 57.28% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp purchased a new position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in the 2nd quarter worth approximately $144,000. Bank of New York Mellon Corp purchased a new position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in the 2nd quarter worth approximately $160,000. Schwab Charles Investment Management Inc. purchased a new position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in the 2nd quarter worth approximately $167,000. BlackRock Inc. boosted its holdings in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 9.4% in the 3rd quarter. BlackRock Inc. now owns 1,727,098 shares of the company’s stock worth $3,230,000 after acquiring an additional 147,828 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its holdings in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 6,107.1% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 12,079,080 shares of the company’s stock worth $27,178,000 after acquiring an additional 11,884,480 shares during the period. Hedge funds and other institutional investors own 15.79% of the company’s stock.

Shares of NYSE:ZOM opened at $1.78 on Friday. Zomedica Pharmaceuticals Corp has a 1 year low of $1.36 and a 1 year high of $2.98.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last issued its earnings results on Thursday, August 9th. The company reported ($0.04) earnings per share (EPS) for the quarter. As a group, equities analysts predict that Zomedica Pharmaceuticals Corp will post -0.11 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Short Interest in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM) Decreases By 2.0%” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2018/11/10/short-interest-in-zomedica-pharmaceuticals-corp-nyseamerican-zom-decreases-by-2-0.html.

About Zomedica Pharmaceuticals Corp (NYSEAMERICAN)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Recommended Story: What is intrinsic value?

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply